Osteosarcoma:

By applying the antibodies TP3 and 9.2.27 and positive IMS by rosetting 40-75% of patients do have positive events in the bone marrow. Material was received before, under and after chemotherapy, and it has been observed that circulating tumour cells in the bone marrow could be used to predict chemotherapy response.